Investinor, Industrifonden invest SEK 96m in Pharmalink

The investment follows the recent announcement of Investinor and Industrifonden's collaborative investment strategy to support life sciences in the Nordic region.

The fresh capital will be used to prepare pivotal studies for the company's Busulipo product and will also be used to complete the pivotal phase IIb study for its Nefecon product.

Furthermore, the funds will go towards finding commercial partners outside of the Nordic region to expand the product's geographical reach, as well as facilitate in-licensing or bolt-on acquisitions.

Company
Stockholm-based Pharmalink is a speciality pharmaceutical company focused on the development of high-value products for niche indications.

It is currently in the late-stage clinical phases for two products, Nefecon and Busulipo, both of which are expected to complete pivotal studies by 2015.
Busulipo is a conditioning agent for use before hematopoietic stem cell transplantation, also known as bone marrow transplantation. It is a lipid complex formulation aimed at improving the safety and stability of the chemotherapy agent busuflan.

Nefecon is designed as a disease-modifying treatment for patients with primary IgA nephropathy, the most common form of glomerulonephritis, at risk of developing end-stage renal disease.

People
Johan Häggblad is managing director of Pharmalink. Ann-Tove Kongsnes is chief investment officer at Investinor. Lennart Hansson is investment director for life science at Industrifonden.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Industrifonden
• Sweden